Digital Cell Analysis And New Applications Will Drive Long Term Upside Potential

Catalysts

About CellaVision

CellaVision develops digital microscopy solutions that help clinical laboratories automate and standardize blood and bone marrow cell analysis.

What are the underlying business or industry changes driving this perspective?

• Ongoing adoption of digital cell analysis in hospital labs in the Americas and across APAC, including integrated health networks that connect smaller sites to central labs, supports broader instrument placements and recurring reagent and software revenue over time.
• Global launch of the largest software upgrade to date, with better user interface, workflow and higher sample throughput on new DI-60 systems, can lift the value of each installed system and support revenue and margin resilience through upgrade sales and higher usage.
• New CellaVision Bone Marrow Aspirate application, already CE marked and now moving through FDA 510(k) review, expands the addressable hematology workload and can add incremental instrument and software package sales, with a positive effect on revenue and gross margin mix.
• Full Ptychographic Microscopy development for hematology, cytology and pathology opens up adjacent diagnostic segments that could increase the long term instrument base and associated consumables, supporting higher earnings potential if adoption scales.
• Expanding cooperation with Sysmex, including extensive training on Software 7.2, the bone marrow solution and connected lab concepts, strengthens go to market execution across regions and can support more consistent instrument volumes and operating leverage in EBITDA and earnings.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more optimistic perspective on CellaVision compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
• The bullish analysts are assuming CellaVision's revenue will grow by 11.1% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from 18.4% today to 24.2% in 3 years time.
• The bullish analysts expect earnings to reach SEK 242.2 million (and earnings per share of SEK 10.09) by about July 2029, up from SEK 134.1 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as SEK189.3 million.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 20.9x on those 2029 earnings, down from 24.3x today. This future PE is lower than the current PE for the GB Medical Equipment industry at 30.9x.
• The bullish analysts expect the number of shares outstanding to remain consistent over the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 5.66%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Continued inventory imbalances with key distributor Sysmex in EMEA and potentially in smaller instruments in the Americas could repeat the situation that contributed to a 14.6% revenue decline to SEK 166 million in Q1 2026, which would keep instrument sales and associated reagent and software revenue under pressure and weigh on earnings.
• Prolonged public health care budget constraints in parts of Europe, where tenders are already being delayed as funding is redirected to defense, could slow adoption of digital microscopy solutions and connected lab concepts, limiting growth in new system placements and pressuring revenue and operating margins over several years.
• If the company’s higher R&D spending of almost SEK 30 million per quarter and the shift toward earlier stage projects do not translate into commercially successful products such as Full Ptychographic Microscopy or wider use in cytology and pathology, capitalized development costs and amortization could rise faster than sales, reducing net margins and earnings.
• Delays or complications in regulatory approvals and commercialization of the Bone Marrow Aspirate application, such as slower than expected FDA 510(k) clearance or a weaker than hoped funnel build, would limit the expected expansion of the hematology workload, which could restrict incremental instrument, software and reagent sales and keep revenue and gross margin growth below current ambitions.
• Ongoing currency headwinds similar to the almost 8% FX impact reported in Q1 2026 could continue to offset organic growth in regions like the Americas and APAC, leading to weaker reported revenue and EBITDA than underlying demand would suggest, which would also dampen earnings growth in reporting currency terms.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for CellaVision is SEK180.0, which represents up to two standard deviations above the consensus price target of SEK168.75. This valuation is based on what can be assumed as the expectations of CellaVision's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of SEK180.0, and the most bearish reporting a price target of just SEK140.0.
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be SEK1.0 billion, earnings will come to SEK242.2 million, and it would be trading on a PE ratio of 20.9x, assuming you use a discount rate of 5.7%.
• Given the current share price of SEK136.6, the analyst price target of SEK180.0 is 24.1% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.